Advertisement

Neurochemical Journal

, Volume 12, Issue 1, pp 107–110 | Cite as

The State of Albumin Thiol Groups in Patients with the First Episode of Schizophrenia

  • V. V. Brilliantova
  • N. V. Smolina
  • T. I. Syreishchikova
  • M. G. Uzbekov
  • G. E. Dobretsov
Clinical Neurochemistry
  • 7 Downloads

Abstract

In this paper, the state of the body’s antioxidant defense was studied using the state of thiol groups in the albumin in patients with their first episode of schizophrenia (FES). We examined 21 patients with the first psychotic attack of schizophrenia; the average severity of the disorders was 75 ± 2 points on the PANSS scale. All patients were examined prior to initiation of the drug therapy. The control group consisted of ten healthy volunteers. The concentration and reactivity of the albumin SH groups was determined in the reaction with dithionitrobenzoic acid. As a result of the study, we found a 24% decrease in the average reactivity of albumin SH groups in the FES group compared with the control group (p = 0.02). Using two parameters, that is, the concentration and reactivity of albumin thiols, it was possible to separate the patient group and the control group, with the probability of a relationship of the patient to the respective group of 86%. Thus, patients with the first episode of schizophrenia before the start of treatment are characterized by significant disturbances in the concentration and reactivity of the albumin SH-groups involved in redox processes in the body.

Keywords

first episode of schizophrenia thiol group of albumin concentration of reduced thiols reaction rate constant Ellman reaction 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Gurovich, I.Ya. and Shmukler, A.B., Pervyi psikhoticheskii epizod (problemy i psikhiatricheskaya pomoshch’) (First Psychotic Episode (Problems and Psychiatric Help)), Moscow: Medpraktika-M, 2010.Google Scholar
  2. 2.
    Ohrmann, P., Siegmund, A., Suslow, T., Pedersen, A., Spitzberg, K., Kersting, A., Rothermundt, M., Arolt, V., Heindel, W., and Pfleiderer, B., J. Psychiatr. Res., 2007, vol. 41, pp. 625–634.CrossRefPubMedGoogle Scholar
  3. 3.
    Uzbekov, M.G., Misionzhnik, E.Yu., Shmukler, A.B., Gurovich, I.Ya., Gryzunov, Yu.A., Smolina, N.V., Kalinina, V.V., Sokolova, T.N., Moskvitina, T.A., and Shevchenko, V.A., Zhurn. Nevrol. i Psikhiatr. im. S.S. Korsakova, 2009, vol. 109, no. 5, pp. 48–52.Google Scholar
  4. 4.
    Uzbekov, M.G., Misionzhnik, E.Yu., Gurovich, I.Y., and Shmukler, A.B., Acta Neuropsychiatrica, 2013, vol. 25, no. 5, pp. P. 268–274.CrossRefPubMedGoogle Scholar
  5. 5.
    Gysin, R., Kraftsik, R., Boulat, O., Bovet, P., Conus, P., Comte-Krieger, E., Polari, A., Steullet, P., Preisig, M., Teichmann, T., Cuenod, M., and Do, K.Q., Antioxid. Redox Signal, 2011, vol. 15, no. 7, pp. 2003–2010.CrossRefPubMedGoogle Scholar
  6. 6.
    Dietrich-Muszalska, A., Olas, B., Glowacki, R., and Bald, E., Neuropsychobiology, 2009, vol. 59, no. 1, pp.1–7.CrossRefPubMedGoogle Scholar
  7. 7.
    Mahadik, S.P. and Scheffer, R.E., Prostaglandins, Leukotrienes and Essential Fatty Acids, 1996, vol. 55, nos. 1–2, pp. 45–54.CrossRefGoogle Scholar
  8. 8.
    Uzbekov, M.G., Sotsial’naya i Klinicheskaya Psikhiatriya, 2005, vol. 15, no. 2, pp. 108–110.Google Scholar
  9. 9.
    Peters, T.J., All about Albumin: Biochemistry, Genetics and Medical Applications, San Diego: Academic Press, 1995.Google Scholar
  10. 10.
    Jocelyn, P.C., Biochemistry of the SH Group, London, New York: Academic Press, 1972.Google Scholar
  11. 11.
    Pikkering, U.F., Sovremennaya analiticheskaya khimiya (Modern Analytical Chemistry), Moscow: Khimiya, 1977.Google Scholar
  12. 12.
    Gryzunov, Y.A., Arroyo, A., Vigne, J.L., Zhao, Q., Tyurin, V.A., Hubel, C.A., Gandley, R.E., Vladimirov, Yu.A., Taylor, R.N., and Kagan, V.E., Arch. Biochem. Biophys., 2003, vol. 413, no. 1, pp. 53–66.CrossRefPubMedGoogle Scholar
  13. 13.
    Vasileva, A., Jakob, M., and Hasko, F., J. Chromatogr., 1981, vol. 216, pp. 279–284.CrossRefPubMedGoogle Scholar
  14. 14.
    Ellman, G.L., Arch. Biochem. Biophys., 1959, vol. 82, no. 1, pp. 70–77.CrossRefPubMedGoogle Scholar
  15. 15.
    Guggenheim, E.A., Thermodynamics: An Advanced Treatment for Chemists and Physicists, Amsterdam: North-Holland Publishing Company, 1949.Google Scholar
  16. 16.
    Ivanova, S.A., Smirnova, L.P., Shchigoreva, Yu.G., Boiko, A.S., Semke, A.V., Uzbekov, M.G., and Bokhan, N.A., Neurochem. J., 2014, vol. 8, no. 1, pp. 66–70.CrossRefGoogle Scholar
  17. 17.
    Uzbekov, M.G., Neurochem. J., 2009, vol. 3, no. 4, pp. 305–308.CrossRefGoogle Scholar
  18. 18.
    Beckman, K.B. and Ames, B.N., Physiol. Rev., 1998, vol. 78, pp. 547–581.CrossRefPubMedGoogle Scholar
  19. 19.
    Ravinder, R., Mahadik, S.P., Mukherjee, S., and Murthy, J.N., Biol. Psychiatry, 1991, vol. 30, pp. 409–412.CrossRefGoogle Scholar
  20. 20.
    Mahadik, S.P., Mukherjee, S., Correnti, E.E., and Scheffer, R.E., Schizophr. Res., 1995, vol. 15, p.66.Google Scholar
  21. 21.
    Mahadik, S.P. and Mukherjee, S., Schizophr. Res., 1996, vol. 19, pp. 1–17.CrossRefPubMedGoogle Scholar

Copyright information

© Pleiades Publishing, Ltd. 2018

Authors and Affiliations

  • V. V. Brilliantova
    • 1
  • N. V. Smolina
    • 1
  • T. I. Syreishchikova
    • 2
  • M. G. Uzbekov
    • 1
    • 4
  • G. E. Dobretsov
    • 3
  1. 1.Moscow Research Institute of PsychiatryMinistry of Health of Russian FederationMoscowRussia
  2. 2.Lebedev Physical InstituteRussian Academy of SciencesMoscowRussia
  3. 3.Research and Clinical Center of Physicochemical MedicineFederal Medical-Biological Agency of the Russian FederationMoscowRussia
  4. 4.MoscowRussia

Personalised recommendations